Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed (Nasdaq: OBIO) has announced its upcoming participation in several major investor conferences, showcasing its commitment to engaging with institutional investors and sharing company developments.
Key conference appearances include:
- Chardan Capital Conference (April 29, 2025) - CEO David Hochman will join a virtual fireside chat at 10:30am ET discussing "Data & Regulatory Catalysts"
- Jefferies Global Healthcare Conference (June 5, 2025) - Management team will conduct a live fireside chat at 3:45pm ET in New York
- H.C. Wainwright BioConnect Conference (May 20, 2025) - Company will deliver a presentation and host one-on-one investor meetings
All virtual events will be accessible through live webcasts and will remain available on Orchestra BioMed's Investor Relations website after the events. The company, which focuses on accelerating high-impact technologies through risk-reward sharing partnerships, will also offer one-on-one meetings with investors at selected conferences.
Orchestra BioMed (Nasdaq: OBIO) ha annunciato la sua partecipazione a diverse importanti conferenze per investitori, dimostrando il suo impegno nel coinvolgere gli investitori istituzionali e nel condividere gli sviluppi aziendali.
Le principali partecipazioni includono:
- Chardan Capital Conference (29 aprile 2025) - Il CEO David Hochman parteciperà a una tavola rotonda virtuale alle 10:30 ET per discutere di "Catalizzatori dati e normativi"
- Jefferies Global Healthcare Conference (5 giugno 2025) - Il team di gestione terrà una tavola rotonda in diretta alle 15:45 ET a New York
- H.C. Wainwright BioConnect Conference (20 maggio 2025) - L'azienda presenterà un intervento e organizzerà incontri individuali con gli investitori
Tutti gli eventi virtuali saranno accessibili tramite webcast in diretta e resteranno disponibili sul sito web delle Relazioni con gli Investitori di Orchestra BioMed dopo la conclusione. L'azienda, specializzata nell'accelerazione di tecnologie ad alto impatto attraverso partnership basate sulla condivisione di rischi e ricompense, offrirà inoltre incontri individuali con investitori in alcune conferenze selezionate.
Orchestra BioMed (Nasdaq: OBIO) ha anunciado su próxima participación en varias conferencias importantes para inversores, mostrando su compromiso con la interacción con inversores institucionales y la comunicación de los avances de la compañía.
Las principales participaciones en conferencias incluyen:
- Chardan Capital Conference (29 de abril de 2025) - El CEO David Hochman participará en una charla virtual a las 10:30 am ET para discutir "Catalizadores de datos y regulatorios"
- Jefferies Global Healthcare Conference (5 de junio de 2025) - El equipo directivo realizará una charla en vivo a las 3:45 pm ET en Nueva York
- H.C. Wainwright BioConnect Conference (20 de mayo de 2025) - La empresa ofrecerá una presentación y llevará a cabo reuniones individuales con inversores
Todos los eventos virtuales serán accesibles mediante transmisiones en vivo y permanecerán disponibles en el sitio web de Relaciones con Inversores de Orchestra BioMed después de los eventos. La compañía, que se enfoca en acelerar tecnologías de alto impacto mediante asociaciones que comparten riesgos y recompensas, también ofrecerá reuniones individuales con inversores en conferencias seleccionadas.
Orchestra BioMed (나스닥: OBIO)는 주요 투자자 컨퍼런스에 곧 참여할 예정임을 발표하며, 기관 투자자와의 소통 및 회사 발전 사항 공유에 대한 의지를 보여주고 있습니다.
주요 컨퍼런스 일정은 다음과 같습니다:
- Chardan Capital Conference (2025년 4월 29일) - CEO David Hochman이 오전 10시 30분(동부시간)에 "데이터 및 규제 촉진제"에 관한 가상 파이어사이드 채팅에 참여합니다
- Jefferies Global Healthcare Conference (2025년 6월 5일) - 경영진 팀이 뉴욕에서 오후 3시 45분(동부시간)에 라이브 파이어사이드 채팅을 진행합니다
- H.C. Wainwright BioConnect Conference (2025년 5월 20일) - 회사가 발표를 진행하고 일대일 투자자 미팅을 주최합니다
모든 가상 이벤트는 라이브 웹캐스트를 통해 접속할 수 있으며, 이벤트 종료 후에도 Orchestra BioMed 투자자 관계 웹사이트에서 시청할 수 있습니다. 위험과 보상을 공유하는 파트너십을 통해 고임팩트 기술 가속화에 집중하는 이 회사는 선정된 컨퍼런스에서 투자자와의 일대일 미팅도 제공합니다.
Orchestra BioMed (Nasdaq : OBIO) a annoncé sa prochaine participation à plusieurs grandes conférences pour investisseurs, témoignant de son engagement à dialoguer avec les investisseurs institutionnels et à partager les évolutions de la société.
Les principales participations aux conférences sont les suivantes :
- Chardan Capital Conference (29 avril 2025) - Le PDG David Hochman participera à une discussion virtuelle à 10h30 ET sur le thème « Catalyseurs de données et réglementaires »
- Jefferies Global Healthcare Conference (5 juin 2025) - L'équipe de direction animera une discussion en direct à 15h45 ET à New York
- H.C. Wainwright BioConnect Conference (20 mai 2025) - La société présentera une intervention et organisera des réunions individuelles avec les investisseurs
Tous les événements virtuels seront accessibles via des webinaires en direct et resteront disponibles sur le site des Relations Investisseurs d’Orchestra BioMed après leur tenue. L’entreprise, qui se concentre sur l’accélération de technologies à fort impact grâce à des partenariats partageant risques et récompenses, proposera également des rencontres individuelles avec les investisseurs lors de conférences sélectionnées.
Orchestra BioMed (Nasdaq: OBIO) hat seine bevorstehende Teilnahme an mehreren wichtigen Investorenkonferenzen bekannt gegeben und damit sein Engagement zur Einbindung institutioneller Investoren und zur Kommunikation von Unternehmensentwicklungen unterstrichen.
Wichtige Konferenzauftritte umfassen:
- Chardan Capital Conference (29. April 2025) - CEO David Hochman wird um 10:30 Uhr ET an einem virtuellen Fireside-Chat zum Thema "Daten- und regulatorische Katalysatoren" teilnehmen
- Jefferies Global Healthcare Conference (5. Juni 2025) - Das Managementteam führt um 15:45 Uhr ET in New York einen Live-Fireside-Chat durch
- H.C. Wainwright BioConnect Conference (20. Mai 2025) - Das Unternehmen wird eine Präsentation halten und Einzelgespräche mit Investoren führen
Alle virtuellen Veranstaltungen sind über Live-Webcasts zugänglich und bleiben nach den Events auf der Investor-Relations-Website von Orchestra BioMed verfügbar. Das Unternehmen, das sich auf die Beschleunigung von Technologien mit hoher Wirkung durch risikobasierte Partnerschaften konzentriert, bietet zudem Einzelgespräche mit Investoren auf ausgewählten Konferenzen an.
- Multiple high-profile investor conference participations showing strong institutional interest
- CEO and management team engaging directly with investors through fireside chats and one-on-one meetings
- Company providing broad market access through live webcasts of presentations
- None.
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company’s participation appear below:
Chardan Capital’s Trending Issues in Drug Development Conference – April 29, 2025 (Virtual)
David Hochman, Orchestra BioMed’s Chairman and Chief Executive Officer, will participate in a fireside chat with Keay Nakae, Senior Research Analyst, Chardan on the topic of “Data & Regulatory Catalysts – Navigating an Evolving Landscape,” which is scheduled for 10:30am ET on Tuesday, April 29. The virtual event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
Jefferies Global Healthcare Conference – June 5, 2025 (New York, NY)
Management will participate in a live fireside chat at 3:45pm ET on Thursday, June 5 and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
Management will also deliver a live presentation at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 and host one-on-one meetings with investors.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (formerly referred to as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
Investor Contact:
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
Kkirkellis@orchestrabiomed.com
FAQ
Which investor conferences will Orchestra BioMed (OBIO) attend in 2025?
When is Orchestra BioMed's (OBIO) presentation at the Chardan Capital conference?
How can investors watch Orchestra BioMed's (OBIO) conference presentations online?
What type of meetings will Orchestra BioMed (OBIO) hold at the Jefferies conference?
Where will Orchestra BioMed (OBIO) present at the H.C. Wainwright conference?
